BioSpace News Archive

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Régie de l’assurance maladie du Québec formulary for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

Bristol Myers Squibb (NYSE: BMY) today announced updated results from the registrational TRIDENT-1 study, demonstrating that repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), continued to show high response rates and durable responses in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC23) being held September 9-12, 2023.

ECRI, the nation’s largest independent patient safety organization, has been awarded a $80,000 grant from The AAMI Foundation to investigate the significance of isolation gown barrier penetration and identify ways to improve the protective features for healthcare workers and patients.

BrightEdge LLC, the American Cancer Society’s venture capital and impact investment arm, published its most recent annual report, featuring how its portfolio of 18 companies has the potential to improve the lives of more than 1.5 million cancer patients and their families.

Catalyst Pharmaceuticals, Inc. today announced that an abstract assessing the prevalence of Lambert-Eaton myasthenic syndrome (“LEMS”) among patients with small cell lung cancer (“SCLC”) in the United States.

10xBio , LLC announced today that it has completed enrollment in a repeat treatment study of its novel injectable drug for submental body contouring.

DNA can be damaged by toxins, radiation, or even normal cell division, but human cells must continually fix DNA breaks to survive.

CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced the closing of its previously announced merger with EIP Pharma Inc.

Acorai, a start-up medical device manufacturer from Sweden, has announced the initiation of a global clinical trial with the enrollment of its first patient in London, UK.